DDInter542 DDInter1731
Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Dicoumarol {u} (Compound) resembles {v} (Compound) Phenprocoumon
Phenprocoumon {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sunitinib
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may lead to a major life threatening interaction when taken with {v} Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sunitinib
Dicoumarol {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) interacts with {v} (Gene) MAST1
MAST1 {u} (Gene) is bound by {v} (Compound) Sunitinib
Dicoumarol {u} (Compound) binds {v} (Gene) GPR35
GPR35 {u} (Gene) regulates {v} (Gene) HERPUD1
HERPUD1 {u} (Gene) is upregulated by {v} (Compound) Sunitinib
Dicoumarol {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sunitinib
Dicoumarol {u} (Compound) resembles {v} (Compound) Acenocoumarol
Acenocoumarol {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Sunitinib
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Etravirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Dicoumarol {u} (Compound) binds {v} (Gene) NQO1
NQO1 {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Dicoumarol (Compound) resembles Phenprocoumon (Compound) and Phenprocoumon (Compound) resembles Warfarin (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sunitinib (Compound)
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may lead to a major life threatening interaction when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib
Dicoumarol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) interacts with MAST1 (Gene) and MAST1 (Gene) is bound by Sunitinib (Compound)
Dicoumarol (Compound) binds GPR35 (Gene) and GPR35 (Gene) regulates HERPUD1 (Gene) and HERPUD1 (Gene) is upregulated by Sunitinib (Compound)
Dicoumarol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib
Dicoumarol (Compound) resembles Acenocoumarol (Compound) and Acenocoumarol (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Sunitinib (Compound)
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Dicoumarol (Compound) binds NQO1 (Gene) and NQO1 (Gene) is bound by Oxaliplatin (Compound) and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib